Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Down on somewhat heavy volume
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(40)
•••
Comment by zwerp2000on Feb 19, 2021 10:20pm
120 Views
Post# 32617306

RE:RE:Down on somewhat heavy volume

RE:RE:Down on somewhat heavy volume

Craig, a few things:

1. take a deep breath. You seem to quite angry and agitated
2. I truly appreciate you defending your boy, JD. I'm sure he would respond to me and others but I know he's very busy working on his website which maybe we will all see within the next few years. 
3. I don't blame JD at all about my investment in Bioaf. I take full responsibility for my own investment decisions. At no point did I blame JD. 
4. I think at some point you have to admit JDs insights and commentary are getting a little tiresome. He's been spewing the same stuff for years, as you know, and really what has actually come true. The company continues to delay, delay, delay. Nothing seems to be getting accomplished. The stock price continues to languish. Yeah, I know some here love JD because he says very positive things so if you're long, you love hearing it. But again, if you look back at his posting history, you will see he's been saying this for years.
5. Can you give me your honest opinion on the company? Are you happy with the company? Are you confident the company is actually going to deliver on their promises? Again, be honest. 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities